Fallopian Tube Cancer Clinical Trials in Cleveland, Ohio

3 studies are recruiting for fallopian tube cancer in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland, Ohio

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

2. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

   The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with pla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   33 in total

   Run by

   Genelux Corporation

   See if you can join NCT05281471 on ClinicalTrials.gov

3. Study of AVZO-021 in Patients With Advanced Solid Tumors

   This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   13 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT05867251 on ClinicalTrials.gov